the number of deaths due to the novel coronavirus has neared 2,700 , as of the end of 24 February.Credit: CDC on Unsplash.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Co-Diagnostics, a US-based molecular diagnostics company, has secured the regulatory CE Mark approval for its Logix Smart Coronavirus COVID-19 Test.

The approval enables the test to be sold as an in vitro diagnostic (IVD) for the diagnosis of SARS-CoV-2 (COVID-19) in all markets accepting CE-marking.

Co-Diagnostics states that the test is now available for purchase from its Utah-based facility.

Last week, the company shipped a few samples of the Research Use Only version of its test to Germany and Italy for distributors to check its quality.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Co-Diagnostics CEO Dwight Egan said: Co-Diagnostics has received overwhelming interest in our novel coronavirus diagnostic from all over the world since first announcing its development a month ago. As the disease has spread from China, so have concerns about the global health community’s ability to contain and control it.

“The first step in containment is a prompt, accurate diagnosis, and we are pleased to provide this product to those areas that are able to utilise a CE-marked IVD to protect their residents and visitors from a disease that has already affected millions.”

Last week, the firm submitted its Logix Smart COVID-19 Test technical file for CE Mark registration.

Logix Smart COVID-19 test uses the company’s CoPrimer technology to identify the presence of ribonucleic acid (RNA) of the novel coronavirus in a real-time RT-PCR kit that targets conserved regions in the virus genome.

Earlier this month, Co-Diagnostics launched a research use only (RUO) CoPrimer test for coronavirus (2019-nCoV).

Meanwhile, the number of deaths due to the novel coronavirus has neared 2,700, as of the end of 24 February. In mainland China, the number of new casualties was 71.

Positive cases have exceeded 80,000 globally, while the number of recoveries increased to more than 27,000.

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now